Mechanistic comparison of Escitalopram S-enantiomer of CITALOPRAM. Belongs to and Kalinin based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
2
Shared Targets
20%
Jaccard Similarity
17%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Escitalopram and Kalinin share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.200 means 20% of the combined target set is bound by both compounds. The IDF-weighted score of 0.173 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Escitalopram and Kalinin have in common?
Escitalopram and Kalinin share 2 molecular targets with a Jaccard similarity of 20%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Escitalopram and Kalinin be combined?
Escitalopram and Kalinin share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Escitalopram or Kalinin?
Both Escitalopram and Kalinin have substantial PubMed research. View their individual profiles for full evidence scores.